📹 HUGE One-Day Pops!

Turn to this sector for short-term wins and long-term outperformance.‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

SPONSORED Editor's Note: Chief Income Strategist Marc Lichtenfeld is making a bold move... He's aiming to show readers of his Lightning Trend Trader the chance at a 3,000% win in a single year. Previously, he's made recommendations that soared as high as 2,381% in 10 months... Click here to learn how you can join him as he tries to beat this record - and score a second year of Lightning Trend Trader for FREE. - Rachel Gearhart, Associate Franchise Publisher BIOTECH INVESTING The Can't-Miss Sector of 2021 Mable Buchanan, Managing Editor, The Oxford Club In the past several weeks, there has been a variety of investments du jour. Some days, the special is crypto... other times, cannabis... and sometimes, it's Wall Street underdogs like GameStop (NYSE: GME). But these emerging (or in some cases, fading) industries' staying power is unproven - and what is hot today may not be hot tomorrow. But one sector consistently delivers sky-high winners regardless of what's "in"... The biotech sector. In this week's episode of his popular YouTube series State of the Market, Chief Income Strategist Marc Lichtenfeld shines a light on this too often overlooked corner of the market where dramatic wins aren't just possible - they're commonplace. SPONSORED Did This Stock-Picking Genius Uncover 2021's BIGGEST Tech Breakthrough... While Fly-Fishing in Alaska?! This financial wizard traveled to remote Alaska... meeting with ultra-wealthy CEOs and businessmen... And oddly, it was on this elite fishing trip that he first glimpsed the KEY to a coming $1 TRILLION market disruption... Here's the true story of his remarkable discovery... and the tiny company that could soar from it. Take Novavax (Nasdaq: NVAX), for example. In this week's episode, Marc reveals how the stock soared after the company reported positive news on COVID-19. But one-time wins aren't the only route to wealth when it comes to biotech investing - and there's a lot more to the biotech sector than just COVID-19 plays. There is a wide variety of exchange-traded funds that can allow you to diversify your holdings while taking advantage of individual stocks' success and trouncing the broader market. You can also follow a trend or track efforts to cure a specific condition. Marc shares his two favorite ways to play the biotech sector - one based on a powerful trend and the other based on a common catalyst - in this week's State of the Market. This is a sector with a strong track record of both short-term pops and long-term outperformance. So regardless of whether you are a trend-tracking trader or a long-term investor, check out this week's episode and consider giving the biotech sector a try. >>Click here to watch.<< Good investing, Mable P.S. If you're interested in giving this thrilling industry a try, don't do it alone. Join Marc in his research service Lightning Trend Trader and receive fast-paced recommendations and a portfolio of the most promising stocks in the biotech sector. Click here to learn more. Leave a Comment MORE FROM WEALTHY RETIREMENT Biotech's Past, Present and Future Why Commodities Are Poised to Outperform Stock Up on an "A" Rated Dividend Facebook Twitter Email Share SPONSORED Is This Strange Device the Linchpin of the 5G Revolution? As This Device Gets Shipped Out to Homes Across the Country, ONE Small Cap Tech Stock Could SKYROCKET. (The Full Story Here...) You are receiving this email because you subscribed to Wealthy Retirement. Wealthy Retirement is published by The Oxford Club. Questions? Check out our FAQs. Trying to reach us? Contact us here. Please do not reply to this email as it goes to an unmonitored inbox. Privacy Policy | Whitelist Wealthy Retirement | Unsubscribe © 2021 The Oxford Club, LLC All Rights Reserved The Oxford Club | 105 West Monument Street | Baltimore, MD 21201 North America: 1.800.589.3430 | International: +1.443.353.4334 | Fax: 1.410.329.1923 Oxfordclub.com The Oxford Club is a financial publisher that does not offer any personal financial advice or advocate the purchase or sale of any security or investment for any specific individual. Members should be aware that although our track record is highly rated by an independent analysis and has been legally reviewed, investment markets have inherent risks and there can be no guarantee of future profits. The stated returns may also include option trades. We expressly forbid our writers from having a financial interest in their own securities recommendations to readers. All of our employees and agents must wait 24 hours after online publication or 72 hours after the mailing of printed-only publications prior to following an initial recommendation. Any investments recommended by The Oxford Club should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company. Protected by copyright laws of the United States and international treaties. The information found on this website may only be used pursuant to the membership or subscription agreement and any reproduction, copying, or redistribution (electronic or otherwise, including on the world wide web), in whole or in part, is strictly prohibited without the express written permission of The Oxford Club, 105 W. Monument Street, Baltimore MD 21201.